Mortality decrease

Newborns with trisomy 13 or 18 benefit from heart surgery

Heart surgery significantly decreases in-hospital mortality among infants with either of two genetic disorders that cause severe physical and intellectual disabilities, according to a new study by a researcher at the Stanford University School of Medicine and his colleagues at the University of Arkansas for Medical Sciences. Trisomy 13 and 18, which result from having extra chromosomes, often cause heart defects. Infants with the conditions generally die within their first year. Many die within weeks, if not days, of being born.

We thought we’d show no difference in survival, but it turns out there’s a marked one.

Thomas Collins

Due to these infants’ short life expectancy, their heart conditions are often treated with standard medical care — blood pressure medication, ventilators and intravenous fluids — but not surgery. Many hospitals rarely give parents the option of surgery for their child. “The thought has been that it doesn’t make sense to undertake a major heart surgery if the patient’s death within a few months is a near certainty,” said Thomas Collins, MD, clinical associate professor of pediatric cardiology at Stanford.

But Collins and his co-authors at Arkansas analyzed the outcomes of the 100 babies with trisomy 13 or 18 in the study who had received heart surgery, and recorded the health impacts. What they found was that patients who underwent heart surgery had a significant decrease in mortality, and that the impact lasted for the next two years. “We thought we’d show no difference in survival, but it turns out there’s a marked one,” Collins said. Collins, the senior author, was on the faculty of the University of Arkansas for Medical Sciences when much of the work was done. The lead author is Katherine Kosiv, MD, a cardiology fellow at the university.

Researchers analyzed data for infants born with two genetic disorders that often cause heart defects and other physical and intellectual disabilities, and found that heart surgery can significantly decrease mortality for these infants.
pixabay

Largest study of its kind

Using data gathered from 44 children’s hospitals across the United States between 2004 and 2015, the researchers reported outcomes for nearly 1,600 patients, the largest study ever of infants with trisomy 13, also known as Patau syndrome, or trisomy 18, also known as Edwards syndrome, Collins said.

The researchers found that heart surgery increased survival and hospital discharge on average from 33 percent to approximately 67 percent for these patients, and that this benefit lasted through two years of follow-up. “When we analyzed the survival curves, the data spoke for themselves,” Collins said. “Especially for trisomy 18, the number of babies that survive more than doubles after surgery.”

Most infants in the study were admitted at less than a day old, and 51 percent of infants in the study who had congenital heart defects died in the hospital or were discharged to hospice. The researchers also found that in-hospital mortality decreased in infants who were older at their admission date, heavier and female, corroborating previous findings.

Challenging the narrative

Collins said his goal is to challenge the narrative surrounding these two conditions, much like how the story of trisomy 21, or Down syndrome, has changed in the last 40 years. “Back in 1975, folks would’ve said there’s nothing we can do to help those babies,” he said. “But now people have proven if you do heart surgery early, patients with Down syndrome can live to adulthood and be active members of their community. The difference it makes for them is tremendous.” Forty percent of people with Down syndrome have congenital heart disease, Collins said. And unlike cases of trisomy 13 and 18, it is now standard-of-care to operate on children with Down syndrome. Scientists aren’t sure why trisomy 13 and 18 are associated with higher rates of congenital heart disease than trisomy 21, and why patient death rates are so much higher.

Collins is certain, however, that trisomy 13 and 18 patients have far more neurological and developmental issues than those with Down syndrome, and is unsurprised at hospitals’ attitudes that surgery is  considered a big risk to take with patients who have a low likelihood of survival. Still, he suspects that the results of this study might shift the paradigm of how babies with trisomy 13 and 18 are cared for. “Surgery gives parents the option to say, ‘We’re going to do everything we can for our baby,’” said Collins. “And, now we’ve shown that heart surgeries could allow parents to take their babies home from the hospital, and have them for two years or beyond, as opposed to two weeks.”

Collins also said that taking care of the patients’ heart problems early on could enable caregivers to then properly analyze other health issues and perform follow-up procedures, such as tracheotomies, to improve the infants’ respiration. His next study, in fact, is looking at all the risk factors other than heart disease in more than 3,000 trisomy 13 and 18 patients and analyzing how their collective health problems fit together. Collins hopes eventually to create a guideline  for pediatric caregivers to determine which problems to treat in which order. 


Source: Stanford Medicine

21.10.2017

Read all latest stories

Related articles

Hypoplastic left heart syndrome (HLHS)

Stem cells might be the key to treating rare cardiac defect

Children's Hospital Los Angeles is announcing participation in the first-ever clinical trial using stem cells from umbilical cord blood to delay or even prevent heart failure in children born with a…

The ESPOIR Study

Professor Axel Haverich and team at the Clinic for Cardiothoracic, Transplant and Vascular Surgery in Hanover Medical School (MHH) have been carrying out research into decellularised heart valves for…

Cause and effect

Diabetes and heart failure: discovering the connection

Men with diabetes are 2.4 times more likely than non-diabetics to suffer heart failure and women are five times more likely. But why? A new Loyola University Chicago Stritch School of Medicine study…

Related products

Research use only (RUO)

Eppendorf - Mastercycler nexus X2

Eppendorf AG

Research use only (RUO)

SARSTEDT - Low DNA Binding Micro Tubes

SARSTEDT AG & CO.

Research use only (RUO)

Shimadzu - CLAM-2000

Shimadzu Europa GmbH